alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Disease mechanisms in lab and animal studies

1,352 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Drebrin in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Advances in experimental medicine and biology 2017 Disease mechanisms

    Alzheimer's disease (AD) is a neurodegenerative disorder accompanied by severe progressive memory and cognitive impairment.

  2. Role of the adhesion molecule F3/Contactin in synaptic plasticity and memory

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular and cellular neurosciences 2016-12-28 Disease mechanisms

    Cell adhesion molecules (CAMs) have a pivotal role in building and maintaining synaptic structures during brain development participating in axonal elongation and pathfinding, glial guidance of neuronal migration, as well as myelination.

  3. Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Drug discovery today 2016-10-27 Disease mechanisms

    Multiple cellular changes have been identified as being involved in Alzheimer's disease (AD) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (Aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation.

  4. Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular neurobiology 2016-10-13 Disease mechanisms

    Synaptic dysfunction has been recognized as an early feature occurring at the onset of Alzheimer's disease (AD).

  5. From eyeless to neurological diseases

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Experimental eye research 2015-11-22 Brain scans and imaging

    Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins, but also other proteins including amyloids (Aβ) leading to the hypothesis that cataracts could be used as "biomarkers" for Alzheimer disease.

  6. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Cell 2020-11-13 Genetics

    To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of 95 PTMs on multiple isoforms of Tau isolated from postmortem human tissue from 49 AD and 42 control subjects.

  7. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020-10-14 Drug development

    Our results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ 25-35 .

  8. Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature structural & molecular biology 2020-09-28 Treatments

    The amyloid cascade hypothesis, according to which the self-assembly of amyloid-β peptide (Aβ) is a causative process in Alzheimer's disease, has driven many therapeutic efforts for the past 20 years.

  9. From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Proteins: Structure, Function, and Bioinformatics 2020-08-03 Treatments

    Alzheimer's disease is one of the most common causes of dementia.

  10. Amyloid-β-independent regulators of tau pathology in Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Neuroscience 2019-11-28 Genetics

    The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment can revert or arrest progression of this disease.

  11. A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP β-CTFs, Not Aβ

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuron 2019-08-12 Genetics

    Familial Alzheimer's disease (fAD) results from mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes.

  12. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Cell reports 2019-08-01 Brain scans and imaging

    Complement pathway overactivation can lead to neuronal damage in various neurological diseases.

  13. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Annual review of neuroscience 2019-07-01 Drug development

    Antisense oligonucleotides represent a novel therapeutic platform for the discovery of medicines that have the potential to treat most neurodegenerative diseases.

  14. The proteostasis network and its decline in ageing

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Molecular cell biology 2019-07-01 Disease mechanisms

    Ageing is a major risk factor for the development of many diseases, prominently including neurodegenerative disorders such as Alzheimer disease and Parkinson disease.

  15. Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99)

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2019-05-01 Down syndrome and Alzheimer's

    Direct measurements of lysosomal pH uncovered a significant elevation (0.6 units) as a basis for slowed LC3 turnover and the inactivation of cathepsin D and other lysosomal hydrolases known to be unstable or less active when lysosomal pH is persistently elevated.

  16. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain research bulletin 2019-01-08 Drug development

    Alzheimer's disease (AD) has been a global concern for years due to its severe implications that affects the quality of life of the patients.

  17. A new era for understanding amyloid structures and disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Molecular cell biology 2018-12-01 Risk factors

    The aggregation of proteins into amyloid fibrils and their deposition into plaques and intracellular inclusions is the hallmark of amyloid disease.

  18. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuron 2018-11-01 Genetics

    Synapse loss and Tau pathology are hallmarks of Alzheimer's disease (AD) and other tauopathies, but how Tau pathology causes synapse loss is unclear.

  19. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2018-10-24 Drug development

    Intracellular neurofibrillary tangles (NFTs) composed of tau protein are a neuropathological hallmark of several neurodegenerative diseases, the most common of which is Alzheimer's disease (AD).

  20. DYRK1A and cognition: A lifelong relationship

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Pharmacology & therapeutics 2018-09-28 Down syndrome and Alzheimer's

    The dosage of the serine threonine kinase DYRK1A is critical in the central nervous system (CNS) during development and aging.

  21. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Chemical reviews 2018-08-10 Disparities

    Neurodegenerative diseases pose a substantial socioeconomic burden on society.

  22. Amyloid toxicity in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Reviews in the neurosciences 2018-08-01 End-of-life care

    A major feature of Alzheimer's disease (AD) pathology is the plaque composed of aggregated amyloid-β (Aβ) peptide.

  23. Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The EMBO journal 2018-07-05 Genetics

    Proteolytic removal of membrane protein ectodomains (ectodomain shedding) is a post-translational modification that controls levels and function of hundreds of membrane proteins.

  24. Tau-targeting therapies for Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Neurology 2018-07-01 Drug development

    Alzheimer disease (AD) is the most common form of dementia.

  25. The exosome of adipose-derived stem cells reduces β-amyloid pathology and apoptosis of neuronal cells derived from the transgenic mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain research 2018-04-03 Biomarkers

    Adipose-derived stem cells (ADSC) have a therapeutic potential for the treatment of neurodegenerative disorders such as Alzheimer's disease (AD).

From across this topic

9 of the 1,352 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics